Cutting Edge SAS announced it received CE Mark for Synthesis™ Acrylic IOL for the treatment of cataract patients.
Montpellier – 17 March 2017 – Synthesis is the latest all-in-one innovations platform allowing for safe, reproducible and MICS (Micro Incision Cataract Surgery) through a sub-2mm incision. Its acrylic copolymer material has been used for more than 17 years in Ophthalmology. The 4-point fixation and C-Edge+ (≤ 5 microns) intraocular lens (IOL) features a 6mm optic and 3 anatomically friendly overall diameters to fit different capsular bag sizes. In addition, Synthesis posterior shift vaulted design allows for superior posterior capsule adhesion.
Synthesis will be implanted in conjunction with a leading quality injector system (preloaded or cartridge loaded options). The IOL is immediately available in both clear or blue-light filtering designs.
The Synthesis monofocal IOL will serve as a platform for future additional optical enhancement and innovation to ease treatment of astigmatism and presbyopia.
For questions regarding this press announcement, please contact Cutting Edge at firstname.lastname@example.org.
Cutting Edge SAS builds experienced and dedicated teams to design, prototype and manufacture high-quality Intraocular Lenses. Cutting Edge’ state-of-the-art facility located in Toulouse, France honours the quality and process sophistication of the medical device industry. Cutting Edge’s creative Research & Development department is continuously searching for new and innovative products and solutions in the field of eye surgery in conjunction with our network of scientific partners, suppliers, and commercial organisation. Cutting Edge provides flexible and agile world-class surgical solutions to serve its worldwide partners. Cutting Edge SAS headquarters are in Montpellier, France.
©2017 Cutting Edge SAS